Effects of the antlered form of Ganoderma lucidum on tumor growth and metastasis in cyclophosphamide-treated mice

Bioscience, Biotechnology and Biochemistry

Volumn 72, Issue 6, 2008, Pages 1399-1408

  Nonaka, Yuji ^a   Ishibashi, Hiroko ^b   Nakai, Masaaki ^a   Shibata, Hiroshi ^a   Kiso, Yoshinobu ^a   Abe, Shigeru ^b  

^a SUNTORY LTD   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Anti tumor activity; Antimetastatic activity; Antlered form of Ganoderma lucidum; Cyclophosphamide; Immunodepression

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; PATHOLOGY; TUMORS;

4 LEVEL; ANTI CANCER DRUGS; ANTI TUMORS; BODY WEIGHT; CYCLOPHOSPHAMIDE (CM); CYTOTOXIC T LYMPHOCYTE (CTL); GANODERMA LUCIDUM; HUMORAL IMMUNITY; IMMUNE RESPONSES; INTERFERON (IFN); LEWIS LUNG CARCINOMA (LLC); NATURAL KILLER; POST TREATMENTS; TUMOR GROWTH;

PHOTOACOUSTIC EFFECT;

CELL EXTRACT; CYCLOPHOSPHAMIDE; CYTOKINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; BODY WEIGHT; CANCER TRANSPLANTATION; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; GANODERMA LUCIDUM; IMMUNOLOGY; MALE; METABOLISM; MOUSE; NATURAL KILLER CELL; NEOPLASM; PATHOLOGY; SPLEEN; TUMOR CELL LINE;

ANIMALS; BODY WEIGHT; CELL EXTRACTS; CELL LINE, TUMOR; CELLS, CULTURED; CYCLOPHOSPHAMIDE; CYTOKINES; KILLER CELLS, NATURAL; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; REISHI; SPLEEN;

GANODERMA LUCIDUM; MUS;

EID: 45849099048     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.70607     Document Type: Article

References (33)

1. Allison, A. C., Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology, 47, 63-83 (2000).
2. Tsung, K., Meko, J. B., Tsung, Y. L., Peplinski, G. R., and Norton, J. A., Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J. Immunol., 160, 1369-1377 (1998).
3. Karnbach, C., Daws, M. R., Niemi, E. C., and Nakamura, M. C., Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population. J. Immunol., 167, 2569-2576 (2001).
4. Chapoval, A. I., Fuller, J. A., Kremlev, S. G., Kamdar, S. J., and Evans, R., Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J. Immunol., 161, 6977-6984 (1998).
5. Goldfarb, R. H., Ohashi, M., Brunson, K. W., Kirii, Y., Kotera, Y., Basse, P. H., and Kitson, R. P., Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide. Anticancer Res., 18, 1441-1446 (1998).
6. Hamuro, J., Kikuchi, T., Takatsuki, F., and Suzuki, M., Cancer cell progression and chemoimmunotherapy-dual effects in the induction of resistance to therapy. Br. J. Cancer, 73, 465-471 (1996).
7. Harada, T., Miura, N., Adachi, Y., Nakajima, M., Yadomae, T., and Ohno, N., Effect of SCG, 1,3-β-Dglucan from Sparassis crispa on the hematopoietic response in cyclophosphamide induced leukopenic mice. Biol. Pharm. Bull., 25, 931-939 (2002).
8. Harada, T., Kawaminami, H., Miura, N. N., Adachi, Y., Nakajima, M., Yadomae, T., and Ohno, N., Mechanism of enhanced hematopoietic response by soluble β-glucan SCG in cyclophosphamide-treated mice. Microbiol. Immunol., 50, 687-700 (2006).
9. Zhang, L., Zhang, M., Zhou, Q., Chen, J., and Zeng, F., Solution properties of antitumor sulfated derivative of α-(1 → 3)-D-glucan from Ganoderma lucidum. Biosci. Biotechnol. Biochem., 64, 2172-2178 (2000).
10. Wang, Y. Y., Khoo, K. H., Chen, S. T., Lin, C. C., Wong, C. H., and Lin, C. H., Studies on the immunomodulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg. Med. Chem., 10, 1057-1062 (2002).
11. Kim, D. H., Shim, S. B., Kim, N. J., and Jang, I. S., β-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol. Pharm. Bull., 22, 162-164 (1999).
12. Sone, Y., Okuda, R., Wada, N., Kishida, E., and Misaki, A., Structures and antitumor activity of the polysaccharides isolated from fruiting body and growing culture of mycelium of Ganoderma lucidum. Agric. Biol. Chem., 49, 2641-2653 (1985).
13. Tasaka, K., Akagi, M., Miyoshi, K., Mio, M., and Makino, T., Anti-allergic constituents in the culture medium of Ganoderma lucidum. I. Inhibitory effect of oleic acid on histamine release. Agents Actions, 23, 153-156 (1988).
14. Tasaka, K., Mio, M., Izushi, K., Akagi, M., and Makino, T., Anti-allergic constituents in the culture medium of Ganoderma lucidum. II. The inhibitory effect of cyclooctasulfur on histamine release. Agents Actions, 23, 157-160 (1988).
15. Nonaka, Y., Shibata, H., Nakai, M., Kurihara, H., Ishibashi, H., Kiso, Y., Tanaka, T., Yamaguchi, H., and Abe, S., Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice. Biosci. Biotechnol. Biochem., 70, 2028-2034 (2006).
16. Kohguchi, M., Kunikata, T., Watanabe, H., Kudo, N., Shibuya, T., Ishihara, T., Iwaki, K., Ikeda, M., Fukuda, S., and Kurimoto, M., Immuno-potentiating effects of the antler-shaped fruiting body of Ganoderma lucidum (Rokkaku-Reishi). Biosci. Biotechnol. Biochem., 68, 881-887 (2004).
17. Masuko, Y., Nakajima, H., Tsubouchi, J., Yamazaki, M., Mizuno, D., and Abe, S., Changes of antitumor immunity of hosts with murine mammary tumors regressed by lentinan: potentiation of antitumor delayed hypersensitivity reaction. Gann, 73, 790-797 (1982).
18. Kodama, N., Komuta, K., Sakai, N., and Nanba, H., Effects of D-fraction, a polysaccharide from Grifola frondosa, on tumor growth involve activation of NK cells. Biol. Pharm. Bull., 25, 1647-1650 (2002).
19. Czop, J. K., and Austen, K. F., Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor. J. Immunol., 135, 3388-3393 (1985).
20. Thornton, B. P., Vetvicka, V., Pitman, M., Goldman, R. C., and Ross, G. D., Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol., 156, 1235-1246 (1996).
21. Taylor, P. R., Brown, G. D., Reid, D. M., Willment, J. A., Martinez-Pomares, L., Gordon, S., and Wong, S. Y., The β-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/ macrophage and neutrophil lineages. J. Immunol., 169, 3876-3882 (2002).
22. Brown, G. D., Herre, J., Williams, D. L., Willment, J. A., Marshall, A. S., and Gordon, S., Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med., 197, 1119-1124 (2003).
23. Takeda, K., Kaisho, T., and Akira, S., Toll-like receptors. Annu. Rev. Immunol., 21, 335-376 (2003).
24. D'Agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., and Garaci, E., Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol., 5, 1205-1212 (2005).
25. Hong, F., Yan, J., Baran, J. T., Allendorf, D. J., Hansen, R. D., Ostroff, G. R., Xing, P. X., Cheung, N. K., and Ross, G. D., Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol., 173, 797-806 (2004).
26. Hong, F., Hansen, R. D., Yan, J., Allendorf, D. J., Baran, J. T., Ostroff, G. R., and Ross, G. D., β-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res., 63, 9023-9031 (2003).
27. Vetvicka, V., Dvorak, B., Vetvickova, J., Richter, J., Krizan, J., Sima, P., and Yvin, J. C., Orally administered marine (1 → 3)-β-D- glucan phycarine stimulates both humoral and cellular immunity. Int. J. Biol. Macromol., 40, 291-298 (2007).
28. Inomata, T., Goodman, G. B., Fryer, C. J., Chaplin, D. J., Palcic, B., Lam, G. K., Nishioka, A., and Ogawa, Y., Immune reaction induced by X-rays and pions and its stimulation by schizophyllan (SPG). Br. J. Cancer Suppl., 27, 122-125 (1996).
29. Kimura, Y., Taniguchi, M., and Baba, K., Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res., 22, 3309-3318 (2002).
30. Wang, G., Zhao, J., Liu, J., Huang, Y., Zhong, J. J., and Tang, W., Enhancement of IL-2 and IFN-γ expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me in vivo. Int. Immunopharmacol., 7, 864-870 (2007).
31. Min, B. S., Nakamura, N., Miyashiro, H., Bae, K. W., and Hattori, M., Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Chem. Pharm. Bull., 46, 1607-1612 (1998).
32. Lin, Z. B., Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J. Pharmacol. Sci., 99, 144-153 (2005).
33. Thyagarajan, A., Jiang, J., Hopf, A., Adamec, J., and Sliva, D., Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion. Int. J. Mol. Med., 18, 657-664 (2006).